Metabolic and Weight Research Peptides, Read From the Satiety Circuit Out

The short version

Feeling full is a signal, not a decision. When food reaches the gut, the intestine releases hormones that travel to the brain and, in effect, say stop eating. One of those hormones is GLP-1 — glucagon-like peptide-1, a hormone released after a meal. The natural version is broken down within minutes of being released.

The peptides briefed on this site are studied because they act on that same system. Semaglutide — the active ingredient in the products marketed as Ozempic, Wegovy and Rybelsus — and retatrutide, which carries no brand name because it is still investigational, are built to imitate the gut's fullness hormones but to survive far longer in the blood, so the stop-eating message keeps arriving between meals rather than fading. AOD-9604 is a different proposition: it was designed to act on fat tissue instead of on appetite, and its human obesity programme was discontinued after the pivotal trial did not show a significant weight reduction against placebo.

That contrast is the organising idea here. Compounds that reach the brain's appetite circuits have moved body weight in large trials. A compound that skips those circuits, so far, has not.

What research peptides are

A peptide is a short chain of amino acids — smaller than a protein, larger than a single building block. GLP-1 itself is a peptide, and so is every compound covered here. Most are administered by injection because digestion would otherwise dismantle them, though two of the three have also been studied in oral formulations.

The word research is doing real work in the phrase research peptide, and it means different things across these three. Semaglutide is an approved prescription medicine with multiple licensed indications. Retatrutide is investigational: it has completed Phase 2 trials, is in Phase 3, and is not approved by any regulator. AOD-9604 is approved for no indication anywhere, is sold as research material, and is prohibited in sport at all times under the anti-doping code as a growth-hormone fragment.

Those three tiers are not interchangeable, and this briefing keeps them separate throughout. A mechanism described in mice is labelled as such. A percentage from a randomised trial is labelled as such. A report from a user community is labelled as anecdote.

The satiety loop, station by station

Appetite is regulated along a chain that runs from the intestine to the brain and back. Reading these compounds by where they enter that chain explains most of what separates them.

In the gut. Enteroendocrine cells release GLP-1 after a meal. The enzyme DPP-4 clears it almost immediately, which is why the native hormone cannot function as a durable appetite signal. Both incretin-class compounds here are engineered around exactly that problem: a modified backbone that resists DPP-4 cleavage, plus a fatty-acid side chain that binds serum albumin and slows clearance.

At the stomach. GLP-1 receptor activity slows gastric emptying. Food stays in the stomach longer, distension persists, and vagal afferents carry that signal upward. This is also the mechanistic root of the class's dominant side effects — the fullness and the nausea come from the same physiology ^[5].

In the brainstem. The area postrema and parabrachial nucleus terminate meals. Rodent mapping shows semaglutide reaching these structures directly ^[6]. The parabrachial nucleus also mediates nausea, so the therapeutic signal and the commonest complaint share an address.

In the hypothalamus. In the arcuate nucleus, appetite-suppressing POMC/CART neurons are activated and appetite-driving NPY/AgRP neurons are inhibited. In rodents this lowered food intake and shifted food preference without reducing energy expenditure ^[6] — the weight change came from intake, not from burning more.

Outside the loop entirely. AOD-9604 targets the adipocyte: inhibition of fat synthesis and up-regulation of beta-3 adrenergic receptor expression in white fat ^[16], with increased fat oxidation ^[17]. No appetite circuit is engaged. Retatrutide, by contrast, keeps both appetite arms and adds a glucagon arm that raises energy expenditure on top of them ^[8].

How this briefing reads the evidence

Structure is consistent across the three compound pages: what it is, how it works, what is shown, what to watch, and what sits outside the evidence. Every quantitative claim carries a bracketed number pointing to the reference list — trial sizes, effect sizes, hazard ratios and durations all trace back to a named source.

The evidence is not distributed evenly, and flattening it would be the most misleading thing this site could do. Semaglutide carries large randomised outcome trials with tens of thousands of participants. Retatrutide carries Phase 2 results and structural pharmacology, with the pivotal programme still running. AOD-9604 carries rodent efficacy, a rabbit joint model, and a human safety record attached to an efficacy failure. Those are three different grades of knowledge and they are labelled as three different grades throughout.

Community reports appear on every compound page, in their own clearly marked section, because they describe what people notice rather than what a protocol measured. They are anecdotal, not clinical evidence, and no doses are ever attached to them. This is a reading desk: it is not a clinic, not a pharmacy, and not a source of medical advice.